Targeting multidrug resistance in cancer
The DOI matches its Crossref record; 267 of the 267 references it cites were found in a registry or an index.
Abstract
Effective treatment of metastatic cancers usually requires the use of toxic chemotherapy. In most cases, multiple drugs are used, as resistance to single agents occurs almost universally. For this reason, elucidation of mechanisms that confer simultaneous resistance to different drugs with different targets and chemical structures - multidrug resistance - has been a major goal of cancer biologists during the past 35 years. Here, we review the most common of these mechanisms, one that relies on drug efflux from cancer cells mediated by ATP-binding cassette (ABC) transporters. We describe various approaches to combating multidrug-resistant cancer, including the development of drugs that engage, evade or exploit efflux by ABC transporters.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“ROS also play an important role in multidrug resistance.”
From Reactive Oxygen Species in Cancer: Current Findings and Future Directions (2021) · cites this paper as [56]
Citations
Cites
1 retracted
Chang, G., & Roth, C. B. (2001) · Science · doi:10.1126/science.293.5536.1793 · Cited by 619
RetractedLipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
Multidrug resistance in cancer: role of ATP–dependent transporters
Gottesman, M. M., Fojo, T., & Bates, S. E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc706 · Cited by 5,536 · cited 1×
“Significance of ABC transporters in cancer Much has been learned about ABC transporters since MDR was first describe”
BackgroundSelf-citationABC Transporters: From Microorganisms to Man
Higgins, C. F. (1992) · Annual Review of Cell Biology · doi:10.1146/annurev.cb.08.110192.000435 · Cited by 3,985 · cited 1×
“The ABC transporter family ABC transporters, named after their distinctive ATP-binding cassette domains, are conserved proteins that typically translocate solutes across cellular membrane”
BackgroundTumour stem cells and drug resistance
Dean, M., Fojo, T., & Bates, S. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1590 · Cited by 3,668 · cited 1×
“According to the cancer stem cell model, this population of drug-resistant pluripotent cells defies treatment and serves as an unrestricted reservoir for drug-resistant tumour relaps”
BackgroundA surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants
Juliano, R. L., & Ling, V. (1976) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(76)90160-7 · Cited by 3,296
Monks, A., Scudiero, D., Skehan, P., Shoemaker, R., Paull, K., Vistica, D., Hose, C., Langley, J., Cronise, P., Vaigro-Wolff, A., et al. (1991) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/83.11.757 · Cited by 3,289
Overexpression of a Transporter Gene in a Multidrug-Resistant Human Lung Cancer Cell Line
Cole, S. P. C., Bhardwaj, G., Gerlach, J. H., Mackie, J. E., Grant, C. E., Almquist, K. C., Stewart, A. J., Kurz, E. U., Duncan, A. M. V., & Deeley, R. G. (1992) · Science · doi:10.1126/science.1360704 · Cited by 3,037
Thiebaut, F., Tsuruo, T., Hamada, H., Gottesman, M. M., Pastan, I., & Willingham, M. C. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.21.7735 · Cited by 2,777
Self-citationA multidrug resistance transporter from human MCF-7 breast cancer cells
Doyle, L. A., Yang, W., Abruzzo, L. V., Krogmann, T., Gao, Y., Rishi, A. K., & Ross, D. D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.26.15665 · Cited by 2,322
Research works printed but not linked: 2
- van der Holt, B. et al. The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis. Blood 106, 2646–2654 (2005). · DOI · Paper page
- Joly, F. J. C. et al. A phase 3 study of PSC 833 in combination with paclitaxel and carboplatin (PC-PSC) versus paclitaxel and carboplatin (PC) alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary cancer of the peritoneum. Proc. Am. Soc. Clin. Oncol. 21, Abstract 806 (2002).
Cited by
Items 901–1,000 of 1,013
Cancer Stem Cells: Powerful Targets to Improve Current Anticancer Therapeutics
Bighetti‐Trevisan, R. L., Sousa, L. O., CASTILHO, R. M., & Almeida, L. O. (2019) · Stem Cells International · doi:10.1155/2019/9618065 · Cited by 70
“Either single or combined treatments target only the bulk of the tumor, and the elevated rates of tumor recurrences are attributed to the accumulation of CSC [42, 43].”
BackgroundSeo, D., Jung, S. M., Park, J. S., Lee, J., Ha, J., Kim, M., & Park, S. H. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.10.039 · Cited by 65
Dihydroartemisinin-Loaded Magnetic Nanoparticles for Enhanced Chemodynamic Therapy
Guo, S., Yao, X., Jiang, Q., Wang, K., Zhang, Y., Peng, H., Tang, J., & Yang, W. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00226 · Cited by 62
Yuan, S., Wang, B., Dai, Q.-Q., Zhang, X., Zhang, J., Zuo, J.-H., Liu, H., Chen, Z., Li, G., Wang, S., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01452 · Cited by 64
Ma, Y., Li, X., Li, A., Yang, P., Zhang, C., & Tang, B. (2017) · Angewandte Chemie · doi:10.1002/ange.201708005 · Cited by 62
Design, Synthesis and In Vitro Antiproliferative Activity of Novel Isatin‐Quinazoline Hybrids
Farès, M., Eldehna, W. M., Abou‐Seri, S. M., Abdel‐Aziz, H. A., Aly, M. H., & Tolba, M. F. (2015) · Archiv der Pharmazie · doi:10.1002/ardp.201400337 · Cited by 62
Misra, R., Das, M., Sahoo, B. S., & Sahoo, S. K. (2014) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2014.08.056 · Cited by 65
Oh, K. T., Lee, E. S., Kim, D., & Bae, Y. H. (2008) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2008.03.003 · Cited by 65
“Furthermore, the multidrug resistance (MDR) of cancer cells is a significant impediment to the efficacy of anticancer drugs (Simon and Schindler, 1994; Links and Brown, 1999; Gottesman et al., 2002; Szakacs et al., 2006).”
BackgroundBiomimetic RNA‐Silencing Nanocomplexes: Overcoming Multidrug Resistance in Cancer Cells
Wang, Z., Wang, Z., Liu, D., Yan, X., Wang, F., Niu, G., Yang, M., & Chen, X. S. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201309985 · Cited by 62
Caveolin-1, a stress-related oncotarget, in drug resistance
Wang, Z., Wang, N., Liu, P., Peng, F., Tang, H., Chen, Q., Xu, R., Dai, Y., Lin, Y. H., Xie, X., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5789 · Cited by 62
“To date, sixteen members have been identified, but only three major ABC drug transporters, including ABCB1 (P-glycoprotein), ABCC1 (multidrug resistance protein 1, MRP1) and ABCG2 (BCRP), are thought to affect cancer chemosensitivity [4].”
BackgroundYan, Y., Li, Z., Xu, X. D., Chen, C., Wei, W., Fan, M., Chen, X., Li, J. J., Wang, Y., & Huang, J. (2016) · BMC Complementary and Alternative Medicine · doi:10.1186/s12906-016-1088-y · Cited by 63
“These results thus not only indicate potential clinic impacts of differentiation treatment with ATRA as single agent for BCSCs in therapy-resistant breast cancers, but also suggest approaches with combination of ATRA and epirubincin, or other standard-anti-breast cancer chemotherapy, as novel therapeutic strategy for…”
ResultWu, Q., Sharma, S., Cui, H., LeBlanc, S. E., Zhang, H., Muthuswami, R., Nickerson, J. A., & Imbalzano, A. N. (2016) · Oncotarget · doi:10.18632/oncotarget.8384 · Cited by 67
“For example, MDR1 inhibitors such as zosuquidar and tariquidar failed in clinical trials despite their high potency and specificity [96].”
InfluentialCell Cycle as an Object of Control
Świerniak, A., Kimmel, M., Śmieja, J., Puszyński, K., & Psiuk-Maksymowicz, K. (2016) · Springer eBooks · doi:10.1007/978-3-319-28095-0_2 · Cited by 62
Zhang, R., Gao, S., Wang, Z., Han, D., Liu, L., Ma, Q., Tan, W., Tian, J., & Chen, X. S. (2017) · Advanced Functional Materials · doi:10.1002/adfm.201701027 · Cited by 64
Joshi, U., Filipczak, N., Khan, M. M., Attia, S. A., & Torchilin, V. P. (2020) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2020.119915 · Cited by 65
A review of synthetic bioactive tetrahydro-β-carbolines: A medicinal chemistry perspective
Wang, J., Gong, F., Liang, T., Xie, Z., Yang, Y.-X., Cao, C., Gao, J., Lu, T., & Chen, X. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113815 · Cited by 63
Tune, B. X. J., Sim, M. S., Poh, C. L., Guad, R. M., Choy, K. W., Hazarika, I., Das, A., Gopinath, S. C. B., Rajan, M., Sekar, M., et al. (2022) · Journal of Oncology · doi:10.1155/2022/3249766 · Cited by 72
Kilmister, E. J., Koh, S. P., Weth, F. R., Gray, C., & Tan, S. T. (2022) · Biomedicines · doi:10.3390/biomedicines10112988 · Cited by 72
Novel drug delivery systems: Insight into self-powered and nano-enabled drug delivery systems
Ewii, U. E., Onugwu, A. L., Nwokpor, V. C., Akpaso, I.-A., Ogbulie, T. E., Aharanwa, B., Chijioke, C., Verla, N., Iheme, C. I., Ujowundu, C. O., et al. (2024) · Nano TransMed · doi:10.1016/j.ntm.2024.100042 · Cited by 68
Innovative Nanomedicine Delivery: Targeting Tumor Microenvironment to Defeat Drug Resistance
Meng, W., Huang, L., Guo, J., Xin, Q., Liu, J., & Hu, Y. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16121549 · Cited by 78
“MDR is usually triggered by the overexpression of ATP-binding cassette transporters (ABC transporters) such as P-glycoprotein (P-gp), which actively expel chemotherapeutic drugs from tumor cells, thus making the drug concentration insufficient for therapeutic effects [95].”
GONZÁLEZ, I., DÉJEAN, S., MARTIN, P. G. P., GONÇALVES, O., BESSE, P., & BACCINI, A. (2009) · Journal of Biological Systems · doi:10.1142/s0218339009002831 · Cited by 62
Min, H., Chung, H., Kim, E., Kim, S., Park, E., & Lee, S. K. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.07.026 · Cited by 66
The pharmacological impact of ATP-binding cassette drug transporters on vemurafenib-based therapy
Wu, C., & Ambudkar, S. V. (2014) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2013.12.001 · Cited by 67
Romagnoli, R., Baraldi, P. G., Salvador, M. K., Prencipe, F., Bertolasi, V., Cancellieri, M., Brancale, A., Hamel, E., Castagliuolo, I., Consolaro, F., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm5008193 · Cited by 61
Wang, S., Chen, R., Zhong, Z., Shi, Z., Chen, M., & Wang, Y. (2014) · The American Journal of Chinese Medicine · doi:10.1142/s0192415x14500803 · Cited by 61
“For instance, it is generally acknowledged that the combination of an anticancer agent with a P-gp or cell survival signaling pathway (such as EGFR, mTOR and NF- B) inhibitor could significantly enhance the therapeutic effect of cancer drug resistance (Szakacs et al., 2006).”
BackgroundChang, C., Wang, Y., Zalath, M. B., Liu, D., Cardillo, T. M., & Goldenberg, D. M. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0219 · Cited by 62
“Whereas the phase II results observed in heavily pretreated patients with mTNBC have led the FDA to grant Breakthrough Therapy Designation to IMMU-132, those who showed early progression of disease, thus failing IMMU-132, may reflect possible drug resistance resulting from one or more preexisting efflux pumps, as SN-3…”
BackgroundJin, Y., Chen, Q., Xu, K., Ren, H., Bao, X., Ma, Y., Wei, Y., & Ma, H. B. (2016) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-016-2816-9 · Cited by 61
“Particularly, the genetic factor is a primary contributor toward an acquired drug resistance [6].”
BackgroundWu, M., Li, J., Lin, X., Wei, Z., Zhang, D., Zhao, B., Liu, X., & Liu, J. (2018) · Biomaterials Science · doi:10.1039/c8bm00226f · Cited by 61
Mannose‐Functionalized Nanoscaffolds for Targeted Delivery in Biomedical Applications
Jing Hua, H. U., Wei, P., Seeberger, P. H., & Yin, J. (2018) · Chemistry - An Asian Journal · doi:10.1002/asia.201801088 · Cited by 61
Li, K., Liu, W., Zhao, Q., Wu, C., Fan, C., Lai, H., & Li, S. (2019) · Phytotherapy Research · doi:10.1002/ptr.6353 · Cited by 61
“Meanwhile, with the prolongation of Dox medication time, breast cancer cells normally develop resistance to Dox and even other chemotherapeutic drugs with different structure and function (Szakács et al., 2006), resulting in chemotherapy failure.”
BackgroundChapter 4 Molecular Mechanisms of Adaptation to Folate Deficiency
Ifergan, I., & Assaraf, Y. G. (2008) · Vitamins and hormones · doi:10.1016/s0083-6729(08)00404-4 · Cited by 75
Famta, P., Shah, S., Chatterjee, E., Singh, H., Dey, B., Guru, S. K., Singh, S. B., & Srivastava, S. (2021) · Current Research in Pharmacology and Drug Discovery · doi:10.1016/j.crphar.2021.100054 · Cited by 65
Hung, T., Hsu, S., Cheng, C., Choo, K., Tseng, C., Chen, T., Lan, Y., Huang, T., Lai, H., Chen, C., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2631 · Cited by 68
“Several mechanisms have been reported to activate MDR in such cancers, including reduced apoptosis, advanced DNA damage repair mechanisms, altered drug metabolism, mutation or over expression of the drug’s targets, drug inactivation, or efflux of the drug from the cell [2].”
BackgroundKnockdown of PgP resensitizes leukemic cells to proteasome inhibitors
Rumpold, H. F., Salvador, C., Wolf, A. M., Tilg, H., Gastl, G. A., & Wolf, D. G. F. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.07.049 · Cited by 62
Side population cells isolated from human osteosarcoma are enriched with tumor‐initiating cells
Yang, M. H., Yan, M., Zhang, R., Li, J., & Luo, Z. (2011) · Cancer Science · doi:10.1111/j.1349-7006.2011.02028.x · Cited by 67
Design and synthesis of new bioisosteres of spirooxindoles (MI-63/219) as anti-breast cancer agents
Kumar, A., Gupta, G., Bishnoi, A. K., Saxena, R., Saini, K. S., Konwar, R., Kumar, S., & Dwivedi, A. (2014) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2014.12.037 · Cited by 64
Zhang, X., Wang, C., Wang, X., Zhong, T., Zhao, Y., Zhang, W.-Q., Ren, W., Huang, D., Zhang, S., Guo, Y., et al. (2015) · International Journal of Nanomedicine · doi:10.2147/ijn.s79840 · Cited by 60
“A large number of P-gp inhibitors have been developed; however, clinical trials using these inhibitors have shown limited success, largely due to the lack of specificity and efficacy.(51) Until now, many attempts have been made to reverse MDR and hence restore the sensitivity of resistant cancer cells to multiple anti…”
Establishment of Optimized MDCK Cell Lines for Reliable Efflux Transport Studies
Gartzke, D., & Fricker, G. (2014) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23901 · Cited by 61
Pathogenesis and Antifungal Drug Resistance of the Human Fungal Pathogen Candida glabrata
Tscherner, M., Schwarzmüller, T., & Kuchler, K. (2011) · Pharmaceuticals · doi:10.3390/ph4010169 · Cited by 59
“consecutive activation of a number of distinct mechanisms operating in all living cells from bacteria to cancer cells [103-106].”
BackgroundKomuro, H., Saihara, R., Shinya, M., Takita, J., Kaneko, S., Kaneko, M., & Hayashi, Y. (2007) · Journal of Pediatric Surgery · doi:10.1016/j.jpedsurg.2007.08.026 · Cited by 60
“ABC transporters, including multiple drug resistance protein (MDR1, ABCB1), MDR related protein (MRP1, ABCC1), and breast cancer–resistant protein (BRCP1, ABCG2), have been shown to contribute to the drug resistance in cancers [25-29].”
BackgroundSriwiriyajan, S., Tedasen, A., Lailerd, N., Boonyaphiphat, P., Nitiruangjarat, A., Deng, Y., & Graidist, P. (2015) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-15-0127 · Cited by 70
“Over a long-term treatment, many patients suffer from MDR, which can reduce therapeutic efficiency and lead to treatment failure and a decrease chance of survival (3, 4).”
BackgroundATP-binding cassette transmembrane transporters and their epigenetic control in cancer: an overview
Arrigoni, E., Galimberti, S., Petrini, M., Danesi, R., & Paolo, A. D. (2016) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2016.1215423 · Cited by 64
“on cellular resistance due to either the specific nature and genetic background of the cancer cell itself, or the genetic changes that follow toxic chemotherapy [31].”
BackgroundLopes-Rodrigues, V., Oliveira, A., Correia‐da‐Silva, M., Pinto, M. M. M., Lima, R. T., Sousa, E., & Vasconcelos, M. H. (2016) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2016.11.023 · Cited by 68
Overcoming Ovarian Cancer Drug Resistance with a Cold Responsive Nanomaterial
Wang, H., Agarwal, P., Zhao, G., Ji, G., Jewell, C. M., Fisher, J. P., Lu, X., & He, X. (2018) · ACS Central Science · doi:10.1021/acscentsci.8b00050 · Cited by 66
RetractedUlixertinib (BVD-523) antagonizes ABCB1- and ABCG2-mediated chemotherapeutic drug resistance
Ji, N., Yang, Y., Lei, Z., Cai, C., Wang, J., Gupta, P., Xian, X., Yang, D., Kong, D., & Chen, Z. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.10.028 · Cited by 62
Ability to Acquire Drug Resistance Arises Early during the Tumorigenesis Process
Yagüe, E., Arance, A. M., Kubitza, L., O’Hare, M. J., Jat, P., Ogilvie, C. M., Hart, I. R., Higgins, C. F., & Raguz, S. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2574 · Cited by 66
“Many of the efforts to overcome clinical drug resistance have focused on modulating the well-characterized effectors, such as P-glycoprotein, or activation of apoptosis, yet the clinical application of this strategy has thus far failed to deliver significant therapeutic benefits (28).”
He, Y., Li, X., Ma, J., Ni, G., Yang, G., & Zhou, S. (2019) · Small · doi:10.1002/smll.201804397 · Cited by 62
Szebényi, K., Füredi, A., Bajtai, E., Sama, S. N., Csiszar, A., Gombos, B., Szabó, P. T., Grusch, M., & Szakács, G. (2023) · Drug Resistance Updates · doi:10.1016/j.drup.2023.101007 · Cited by 66
Self-citationMiR-181b sensitizes glioma cells to teniposide by targeting MDM2
Sun, Y.-C., Wang, J., Guo, C., Sai, K., Wang, J., Chen, F.-R., Yang, Q., Chen, Y.-S., Wang, J., To, S. S. T., et al. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-611 · Cited by 60
“Although the initial response of teniposide is remarkable, tumor resistance develops rapidly after prolonged administration [17].”
BackgroundAbouzeid, A. H., Patel, N. R., Sarısözen, C., & Torchilin, V. P. (2014) · Pharmaceutical Research · doi:10.1007/s11095-013-1295-x · Cited by 60
“The third and most commonly reported mechanism is the increased energy-dependent efflux of hydrophobic drugs from the cell by ATP-binding cassette (ABC) transporter transmembrane proteins such as MDR-1 or P-glycoprotein (P-gp) (2).”
Shi, Z., Jain, S. K., Kim, I., Peng, X., Abraham, I., Youssef, D. T. A., Fu, L., Sayed, K. A. E., Ambudkar, S. V., & Chen, Z. (2007) · Cancer Science · doi:10.1111/j.1349-7006.2007.00554.x · Cited by 59
Yang, Z., Wu, W., Wang, J., Liu, L., Li, L., Yang, J., Wang, G., Cao, D., Zhang, R., Tang, M., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500849z · Cited by 59
Mass Spectrometry Quantifies Protein Interactions—From Molecular Chaperones to Membrane Porins
Hopper, J. T. S., & Robinson, C. V. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201403741 · Cited by 71
Sun, L., Liu, S., Wang, R., Jiang, Y., Zhang, Y., Zhang, J., Bao, L., Kaltenboeck, L., Dunham, R. A., Waldbieser, G., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0109666 · Cited by 66
“The expression of ABCB5 was also significantly associated with tumor progression and recurrence, acting as an energy-dependent drug efflux transporter and function during the multidrug resistance process [55,56].”
Barile, E., Borriello, M., Pietro, A. D., Doreau, A., Fattorusso, C., Fattorusso, E., & Lanzotti, V. (2008) · Organic & Biomolecular Chemistry · doi:10.1039/b800485d · Cited by 62
Wang, X.-K., To, K. K. W., Huang, L.-Y., Xu, J.-H., Yang, K., Wang, F., Huang, Z.-C., Ye, S., & Fu, L. (2014) · Oncotarget · doi:10.18632/oncotarget.2647 · Cited by 59
“Intense research on the mechanism of MDR has focused on the overexpression of the superfamily of ATP-binding cassette (ABC) transporters that function as active drug efflux pumps resulting in the reduction of cellular accumulation of drugs [1].”
BackgroundLai, C.-K., Chen, Y., Lin, C., Lin, H., Kao, M.-C., Huang, M.-Z., Lin, Y.-H., Chiang-Ni, C., Chen, C., Lo, U., et al. (2016) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2016.00009 · Cited by 59
“One example of therapeutic resistance involves the presence of a major molecular efflux pump in cell membranes that enables cancer cells to bypass drug toxicity or alter cellular processes between the cytoplasm and the nucleus (Szakacs et al., 2006).”
BackgroundEvading P-glycoprotein mediated-efflux chemoresistance using Solid Lipid Nanoparticles
Cavaco, M. C., Pereira, C. A., Kreutzer, B., Gouveia, L. F., Lima, B. S., Brito, M. A., & Videira, M. (2016) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2016.10.024 · Cited by 64
Palko-Łabuz, A., Środa-Pomianek, K., Uryga, A., Kostrzewa-Susłow, E., & Michalak, K. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.01.053 · Cited by 60
Deciphering the roles of lncRNAs in breast development and disease
Richard, J. L. C., & Eichhorn, P. J. A. (2018) · Oncotarget · doi:10.18632/oncotarget.24591 · Cited by 66
de Klerk, D. J., Honeywell, R. J., Jansen, G., & Peters, G. J. (2018) · Cancers · doi:10.3390/cancers10120503 · Cited by 64
The ABCG2 multidrug transporter is a pump gated by a valve and an extracellular lid
Khunweeraphong, N., Szöllősi, D., Stockner, T., & Kuchler, K. (2019) · Nature Communications · doi:10.1038/s41467-019-13302-2 · Cited by 64
Alginate-based drug oral targeting using bio-micro/nano encapsulation technologies
Wagle, S. R., Kovačević, B., Walker, D., Ionescu, C. M., Shah, U., Stojanović, G. M., Kojić, S., Mooranian, A., & Al‐Salami, H. (2020) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2020.1789587 · Cited by 61
Stein, U., Walther, W., Stege, A., Kaszubiak, A., Fichtner, I., & Lage, H. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300304 · Cited by 68
“[ 3 ] It is therefore very important to develop new strategies that are capable of circumventing MDR1/P-gp-mediated MDR thereby leading to better clinical outcomes.”
BackgroundNuclear receptor-like transcription factors in fungi
Näär, A. M., & Thakur, J. K. (2009) · Genes & Development · doi:10.1101/gad.1743009 · Cited by 61
“In humans, acquired MDR in tumor cells hampers cancer chemotherapy and is frequently resulting from amplification and/or increased expression ofmembers of the P-glycoprotein family of ATP-binding cassette (ABC) drug transporters (Deeley et al. 2006; Szakacs et al. 2006).”
BackgroundMolecular Mechanisms of Drug Resistance in Single-Step and Multi-Step Drug-Selected Cancer Cells
Calcagno, A. M., & Ambudkar, S. V. (2009) · Methods in molecular biology · doi:10.1007/978-1-60761-416-6_5 · Cited by 60
Mousavi, S. M., Soroshnia, S., Hashemi, S. A., Babapoor, A., Ghasemi, Y., Savardashtaki, A., & Amani, A. M. (2019) · Drug Metabolism Reviews · doi:10.1080/03602532.2019.1582661 · Cited by 58
“Other treatments are known to offer significant disadvantages including severe adverse reactions (Szak acs et al. 2006; Splinter 2007) and low competence against resistant cancer cells Figure 4.”
BackgroundDiscovery of Encequidar, First-in-Class Intestine Specific P-glycoprotein Inhibitor
Smolinski, M. P., Urgaonkar, S., Pitzonka, L. B., Cutler, M. J., Lee, G., Suh, K. H., & Lau, J. Y. N. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01826 · Cited by 62
Ahar, M. J., Barar, J., Alizadeh, A. M., Davaran, S., Omidi, Y., & Rashidi, M. (2015) · Journal of drug targeting · doi:10.3109/1061186x.2015.1058801 · Cited by 59
“Of these, functional upregulation of efflux transport machineries of tumour cells can profoundly elicit the resistancy in the cancer cells, which can markedly lower the intracellular accumulation and hence efficacy of anticancer agents [5,6].”
BackgroundRothweiler, F., Michaelis, M., Brauer, P., Otte, J., Riecken, K., Fehse, B., Doerr, H. W., Wiese, M., Kreuter, J., Al‐Abed, Y., et al. (2010) · Neoplasia · doi:10.1593/neo.10856 · Cited by 58
Loo, T. W., & Clarke, D. M. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.10.006 · Cited by 63
ABC Transporters in Multi-Drug Resistance and ADME-Tox of Small Molecule Tyrosine Kinase Inhibitors
Deng, J., Shao, J., Markowitz, J. S., & An, G. (2014) · Pharmaceutical Research · doi:10.1007/s11095-014-1389-0 · Cited by 65
“In intrinsic resistance, tumors fail to respond to chemotherapy from the outset; whereas acquired resistance is the situation that tumors initially respond to chemotherapy but eventually become insensitive to treatment upon relapse [95].”
Multifunctional Albumin Nanoparticles As Combination Drug Carriers for Intra‐Tumoral Chemotherapy
Cui, M., Naczynski, D. J., Zevon, M., Griffith, C. K., Sheihet, L., Poventud‐Fuentes, I., Chen, S., Roth, C. M., & Moghe, P. V. (2013) · Advanced Healthcare Materials · doi:10.1002/adhm.201200467 · Cited by 58
Feng, X., Zhao, L., Gao, S., Song, X., Dong, W., Zhao, Y., Zhou, H., Cheng, L., Miao, X., & Li, J. (2015) · Gene · doi:10.1016/j.gene.2015.12.028 · Cited by 61
Li, X., Mu, J., Liu, F., Tan, E., Khezri, B., Webster, R. D., Yeow, E. K. L., & Xing, B. (2015) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.5b00170 · Cited by 58
Development of efflux pump inhibitors in antituberculosis therapy
Song, L., & Wu, X. (2016) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2016.04.007 · Cited by 65
“1, P-gp is composed of two hydrophobic transmembrane domains (TMD1 and TMD2) and two nucleotide-binding domains (NBD1 and NBD2) [14,15].”
BackgroundDömötör, O., Pape, V. F. S., May, N. V., Szakács, G., & Enyedy, É. A. (2017) · Dalton Transactions · doi:10.1039/c7dt00439g · Cited by 58
Self-citationManagò, S., Migliaccio, N., Terracciano, M., Napolitano, M., Martucci, N. M., Stefano, L. D., Rendina, I., Luca, A. C. D., Lamberti, A., & Rea, I. (2017) · Journal of Biophotonics · doi:10.1002/jbio.201700207 · Cited by 58
miR‐381 overcomes cisplatin resistance in breast cancer by targeting MDR1
Yi, D., Xu, L., Wang, R., Lu, X., & Sang, J. (2018) · Cell Biology International · doi:10.1002/cbin.11071 · Cited by 58
“Nevertheless, the existence and development of chemoresistance tremendously restricted and hampered the curative effect of chemotherapy drugs for cancers, including breast cancer (Szak acs et al., 2006; Coley, 2008).”
BackgroundYao, X., Ma, S., Peng, S., Zhou, G., Xie, R., Jiang, Q., Guo, S., He, Q., & Yang, W. (2020) · Advanced Healthcare Materials · doi:10.1002/adhm.201901582 · Cited by 58
Self-Organizing Maps for Identification of New Inhibitors of P-Glycoprotein
Kaiser, D., Terfloth, L., Kopp, S., Schulz, J., de Laet, R., Chiba, P., Ecker, G. F., & Gasteiger, J. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm060604z · Cited by 61
The role of membrane transporters in drug delivery to brain tumors
Nies, A. T. (2007) · Cancer Letters · doi:10.1016/j.canlet.2006.12.023 · Cited by 64
“These compounds include several classes of anti-cancer drugs, such as Vinca alkaloids, anthracyclines, epipodophyllotoxins, taxanes, tyrosine kinase inhibitors, and camptothecins [29], as well as other therapeutic agents, e.”
BackgroundInfluentialMulti-Target ABC Transporter Modulators: What Next and Where to Go?
Stefan, S. M. (2019) · Future Medicinal Chemistry · doi:10.4155/fmc-2019-0185 · Cited by 60
Yamagishi, N., Nakao, R., Kondo, R., Nishitsuji, M., Saito, Y., Kuga, T., Hatayama, T., & Nakayama, Y. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.04.125 · Cited by 60
Zhu, Z., Shen, H., Xu, J., Fang, Z., Wo, G., Ma, Y., Yang, K., Wang, Y., Yu, Q., & Tang, J. (2023) · Drug Resistance Updates · doi:10.1016/j.drup.2023.100974 · Cited by 59
Ma, H., Cheng, L., Hao, K., Li, Y.-P., Song, X., Zhou, H., & Li, J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0085113 · Cited by 57
“Numerous reports have focused on the mechanisms of MDR of tumor cells, for example the expression of drug transporting pumps, changes in the targets of anticancer drugs, decrease of drug activity, as well as changes in apoptosis regulatory pathways that contribute to MDR [2–4].”
Retractedvan Vlerken, L. E., Duan, Z., Little, S. R., Seiden, M. V., & Amiji, M. M. (2010) · The AAPS Journal · doi:10.1208/s12248-010-9174-4 · Cited by 57
“Although a number of therapeutic strategies have been developed to modulate the cellular mechanisms whereby MDR is thought to arise (2, 18 ), the manipulation of the CER metabolic pathway has emerged as a promising therapeutic strategy to overcome MDR in cancer (19).”
BackgroundOthman, N., & Nagoor, N. H. (2014) · BioMed Research International · doi:10.1155/2014/318030 · Cited by 61
“However, multiple administration of DDP results in the development of drug resistance leading to failure of treatment, as demonstrated by tumor growth or tumor relapse [78, 83].”
BackgroundRecent trends in cancer drug resistance reversal strategies using nanoparticles
Palakurthi, S., Yellepeddi, V., & Vangara, K. K. (2012) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2012.665365 · Cited by 60
“The most prevalent and clinically relevant form of tumor resistance is the MDR. MDR is mediated by several ABC transporters like P-gp, MDR-associated protein 1 (MRP1), ABCG2 (also known as mitoxantrone resistance protein (MXR) and BCRP [8].”
BackgroundInfluentialObatoclax and Lapatinib Interact to Induce Toxic Autophagy through NOXA
Tang, Y., Hamed, H. A., Cruickshanks, N. A., Fisher, P. B., Grant, S., & Dent, P. (2012) · Molecular Pharmacology · doi:10.1124/mol.111.076851 · Cited by 63
“As with all drugs, lapatinib is metabolized by several enzymes such as cytochrome P450 members, CYP3A4 and CYP3A5, and can be secreted from cell ATP-binding cassette drug transporter excretion by P-glycoprotein (Szakács et al., 2006).”
BackgroundBush, T. L., Payton, M. N., Heller, S., Chung, G., Hanestad, K., Rottman, J. B., Loberg, R. D., Friberg, G. R., Kendall, R. L., Saffran, D. C., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-1178 · Cited by 63
Weylandt, K. H., Nebrig, M., Jansen-Rosseck, N., Amey, J. S., Carmena, D., Wiedenmann, B., Higgins, C. F., & Sardini, A. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0475 · Cited by 59
“Although it has been shown that target modification can lead to drug resistance, it is frequently the emergence of expression of ATP-binding cassette transporters, responsible for drug efflux from cancer cells, that actually leads to resistance (1).”
BackgroundZhu, X., Li, Y., Shen, H., Li, H., Long, L., Hui, L., & Xu, W. (2012) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gms099 · Cited by 63
Invited review: Architectures and mechanisms of ATP binding cassette proteins
Hopfner, K. (2016) · Biopolymers · doi:10.1002/bip.22843 · Cited by 56
Cisplatin and doxorubicin dual-loaded mesoporous silica nanoparticles for controlled drug delivery
Li, H., Yu, H., Zhu, C., Hu, J., Du, M., Zhang, F., & Yang, D. (2016) · RSC Advances · doi:10.1039/c6ra17213j · Cited by 57
Wang, R., Bai, J., Deng, J., Fang, C., & Chen, X. S. (2017) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.6b15200 · Cited by 58
Zhao, Y. H., Wang, S., Chen, A., & Kankala, R. K. (2022) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2022.214765 · Cited by 58
Relationship between miRNA and ferroptosis in tumors
Dai, S., Li, F., Long, H., Zhou, Z.-W., Luo, H., Xu, S., & Gao, L. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.977062 · Cited by 60
“In particular, some malignant tumors have developed resistance to traditional treatment methods, making the treatment effect poor (Szakács et al., 2006; Du and Shim, 2016; Sharma et al., 2017; O’Donnell et al., 2019).”
BackgroundTao, L., Zhu, F., Xu, F., Chen, Z., Jiang, Y., & Chen, Y. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.09.019 · Cited by 56
Kathawala, R. J., Wang, Y., Ashby, C. R., & Chen, Z. (2013) · 癌症:英文版 · doi:10.5732/cjc.013.10122 · Cited by 60
“com Chinese Anti-Cancer Association CACA 223 One known cause of multidrug resistance (MDR) to cancer chemotherapy is the overexpression of ATP-binding cassette (ABC) transporters on the membranes of cancer cells([1]).”
Background
Metadata
- Authors
- Szakács, G., Paterson, J. K., Ludwig, J. A., Booth-Genthe, C., & Gottesman, M. M.
- Affiliations
- Institute of Molecular Life Sciences (HU)
- National Institutes of Health (US)
- Corresponding author
- Gottesman, Michael M.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2006-03
- Volume
- 5
- Issue
- 3
- Pages
- 219-234
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2055904567
- Cited by
- 3,609
- References
- 265
- Citations by year
- 2026: 62 · 2025: 119 · 2024: 149 · 2023: 196 · 2022: 172 · 2021: 210 · 2020: 226 · 2019: 194 · 2018: 234 · 2017: 228 · 2016: 246 · 2015: 247 · 2014: 232 · 2013: 230 · 2012: 199
- FWCI
- 11.77
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Keywords
- multidrug resistance, ABC transporters, drug efflux, chemoresistance, ABC transporter inhibitors, cancer chemotherapy
- MeSH terms
- Animals, Antineoplastic Agents, Humans, Neoplasms, Drug Resistance, Multiple, ATP-Binding Cassette Transporters, Drug Resistance, Neoplasm
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.